Blister Missing Complaints in Pharma

by
Blister Missing Complaints in Pharma: Causes, CAPA & GMP

Blister Missing Complaints in Pharmaceuticals: Root Causes, Investigation & Remedial Actions Blister Missing Complaints in Pharmaceutical Manufacturing: Root Causes, Investigation and Remedial Actions Blister packaging is one of the most widely used packaging systems in the pharmaceutical industry because it provides excellent product protection, enhances patient compliance, and allows easy visual inspection of tablets and … Read more

SUPAC Guidance: Complete FDA Guide to Post-Approval Changes

by
SUPAC Guidance flowchart showing FDA post-approval change categories for pharmaceutical manufacturing.

SUPAC Guidance for Pharmaceutical Industry – Complete FDA Guide to Scale-Up and Post-Approval Changes SUPAC Guidance: A Complete Guide to Scale-Up and Post-Approval Changes in the Pharmaceutical Industry The pharmaceutical industry operates under one of the most stringent regulatory frameworks in the world. After receiving FDA approval, manufacturers often need to make changes to formulations, … Read more

VARIATION FILING IN EUROPE

by

Variation Filing in Europe: A Complete Guide for Pharmaceutical Regulatory Professionals Variation Filing in Europe – Complete Regulatory Guide Once a medicinal product receives marketing authorization in the European Union (EU), its lifecycle does not end. Pharmaceutical companies frequently implement changes to manufacturing processes, analytical methods, packaging materials, manufacturing sites, quality controls, safety information, and … Read more

TYPES OF VARIATION FILING IN USA

by

Types of Variation Filing in USA for Pharma: PAS, CBE-30, CBE-0 & Annual Report | Pharmashare Types of Variation Filing in USA for Pharma: PAS, CBE-30, CBE-0 & Annual Report Explained Last Updated: April 2026 | For: Regulatory Affairs, CMC, QA Professionals If you work in Regulatory Affairs for US FDA submissions, you face this … Read more

483 Observations related to Inadequate Investigations

by

FDA 483 Observations Related to Inadequate Investigations in Pharmaceutical Manufacturing FDA Form 483 Observations Related to Inadequate Investigations in Pharmaceutical Manufacturing In the pharmaceutical industry, investigations are a critical component of the Quality Management System (QMS). Whether dealing with deviations, out-of-specification (OOS) results, customer complaints, environmental monitoring excursions, or product quality defects, a thorough and … Read more

483 Observations on CAPA and CAPA Effectiveness

by

FDA 483 Observations on CAPA & CAPA Effectiveness 2026 | Pharma Compliance Guide FDA 483 Observations on CAPA & CAPA Effectiveness: Why 42% of Warning Letters Quote This Updated: April 21, 2026 | Category: QA & Compliance | Reading Time: 9 min “Corrective and Preventive Action procedures are not adequate.” If you’ve seen a USFDA … Read more

CAPA AND CAPA EFFECTIVENESS IN PHARMACEUTICAL INDUSTRY

by

CAPA and CAPA Effectiveness in Pharmaceutical Industry CAPA and CAPA Effectiveness in the Pharmaceutical Industry “CAPA Process in Pharmaceutical Quality Management System” Corrective and Preventive Action (CAPA) is one of the most critical elements of a Pharmaceutical Quality System (PQS). Regulatory agencies worldwide, including the FDA, EMA, MHRA, and WHO, expect pharmaceutical manufacturers to establish … Read more

Empty Pockets in Blister Packaging

by

Empty Pockets in Pharmaceutical Blister Packaging: Causes and Troubleshooting Empty Pockets in Pharmaceutical Blister Packaging: Causes, Impact, and Troubleshooting Blister packaging is one of the most widely used packaging formats in the pharmaceutical industry due to its ability to provide product protection, tamper evidence, and patient convenience. However, one of the common challenges encountered during … Read more